Intellia Therapeutics
About
What does Intellia Therapeutics do?
Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing curative therapeutics using its proprietary CRISPR/Cas9 technology. The company aims to precisely edit genes within the body to treat a range of severe diseases, including genetic disorders and cancer, offering potentially transformative treatments for patients.
What is Intellia Therapeutics's revenue?
StartupHub estimates Intellia Therapeutics's annual revenue at $128.6M (range $18.0M to $307.6M, 29% confidence), based on comparable companies in the sector.
What is Intellia Therapeutics's valuation?
StartupHub estimates Intellia Therapeutics's effective valuation at $1.1B (range $775.0M to $1.9B, 10% confidence), based on comparable companies in the sector.
How much funding has Intellia Therapeutics raised?
Intellia Therapeutics has raised a total of $310M in funding. The most recent round on record is Series C.
Where is Intellia Therapeutics headquartered?
Intellia Therapeutics is headquartered in Cambridge, United States.
When was Intellia Therapeutics founded?
Intellia Therapeutics was founded in 2014.
What industry does Intellia Therapeutics operate in?
Intellia Therapeutics operates in Biotech, MedTech, Genomics, Drug Discovery, Clinical Trials, CRISPR.
No comments yet. Be the first to share your take.